Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up

被引:95
作者
Barbareschi, M
Caffo, O
Veronese, S
Leek, RD
Fina, P
Fox, S
Bonzanini, M
Girlando, S
Morelli, L
Eccher, C
Pezzella, F
Doglioni, C
Palma, PD
Harris, A
机构
[1] OSPED S CHIARA,DEPT ONCOL,TRENT,ITALY
[2] OSPED S CHIARA,DEPT SURG,TRENT,ITALY
[3] OSPED NIGUARDA CA GRANDA,DEPT HISTOPATHOL,MILAN,ITALY
[4] UNIV OXFORD,NUFFIELD DEPT PATHOL,OXFORD,ENGLAND
[5] GLAXO CORP,DEPT BIOSTAT,VERONA,ITALY
[6] EUROPEAN INST ONCOL,DEPT HISTOPATHOL,MILAN,ITALY
[7] CITY HOSP,DEPT HISTOPATHOL,BELLUNO,ITALY
[8] UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOL MED,OXFORD OX3 9DU,ENGLAND
关键词
breast cancer; human; Bcl-2; estrogen receptors; p53; protein; survival analysis; immunohistochemistry;
D O I
10.1016/S0046-8177(96)90307-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Bcl-2 and p53 gene products (Bcl-2, p53) are important regulators of apoptosis and cell proliferation, and their immunohistochemical expression may help to identify high-risk breast cancer patients. The authors evaluated p53 and Bcl-2 immunoreactivity in 178 node-negative breast cancers (NNBC) with long-term follow-up (median, 60 months). Bcl-2 was seen in 111 (62%) cases, and was significantly associated with small tumor size, nonductal morphology, low tumor grade, estrogen-receptor (ER) positivity, and p53 negativity. p53 overexpression tie, > 15% reactive nuclei) was observed in 31 (17%) cases, and was associated with lower age, large tumor size, ductal morphology, high tumor grade, negative ER status, and lack of Bcl-2 immunoreactivity. In univariate analysis, the variables associated with short relapse-free survival (RFS) were large tumor size (P = .002), high histological grade (P = .01), high mitotic count (P = .03), and high Nottingham prognostic index (NPI) (P = .0002). In multivariate analysis (final model), only the NPI was of independent prognostic value concerning RFS. Copyright (C) 1996 by W.B. Saunders Company
引用
收藏
页码:1149 / 1155
页数:7
相关论文
共 50 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]  
Azzopardi JG., 1979, PROBLEMS BREAST PATH
[3]   MITOSIS COUNTING IN TUMORS [J].
BAAK, JPA .
HUMAN PATHOLOGY, 1990, 21 (07) :683-685
[4]  
Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106
[5]   P53 AND C-ERBB-2 PROTEIN EXPRESSION IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY INCLUDING CORRELATIONS WITH RECEPTOR STATUS, PROLIFERATION MARKERS, AND CLINICAL STAGE IN HUMAN BREAST-CANCER [J].
BARBARESCHI, M ;
LEONARDI, E ;
MAURI, FA ;
SERIO, G ;
PALMA, PD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :408-418
[6]  
BAROU RC, 1995, INT J CANCER, V60, P854
[7]  
BHARGAVA V, 1994, AM J PATHOL, V145, P535
[8]   MITOTIC FREQUENCY AS A PROGNOSTIC FACTOR IN BREAST-CANCER [J].
BIESTERFELD, S ;
NOLL, I ;
NOLL, E ;
WOHLTMANN, D ;
BOCKING, A .
HUMAN PATHOLOGY, 1995, 26 (01) :47-52
[9]   ABNORMAL P53 IMMUNOREACTIVITY AND PROGNOSIS IN NODE-NEGATIVE BREAST CARCINOMAS WITH LONG-TERM FOLLOW-UP [J].
BOSARI, S ;
LEE, AKC ;
VIALE, G ;
HEATLEY, GJ ;
COGGI, G .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 421 (04) :291-295
[10]  
CAFFO O, 1996, IN PRESS CLIN CANC R